In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals

Clinical Therapeutics

Volumn 31, Issue 11, 2009, Pages 2678-2688

  Eagye, Kathryn J ^a   Kuti, Joseph L ^a   Sutherland, Christina A ^a   Christensen, Henry ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

antibiotic resistance; E coli; P aeruginosa; pharmacodynamics; surveillance

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MULTIDRUG RESISTANCE; NONHUMAN; PREDICTION; PSEUDOMONAS AERUGINOSA; UNITED STATES; WARD; WOUND INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; UNITED STATES;

EID: 74549167462     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.021     Document Type: Article

References (29)

1. Jones R.N. Resistance patterns among nosocomial pathogens: Trends over the past few years. Chest. 119 Suppl 2 (2001) 397S-404S
2. Kollef M.H. Inadequate antimicrobial treatment: An important determinant of outcome for hospitalized patients. Clin Infect Dis. 31 Suppl 4 (2000) S131-S138
3. Albrecht S.J., Fishman N.O., Kitchen J., et al. Reemergence of gram-negative health care-associated bloodstream infections. Arch Intern Med. 166 (2006) 1289-1294
4. Lautenbach E., and Polk R.E. Resistant gram-negative bacilli: A neglected healthcare crisis?. Am J Health Syst Pharm. 64 Suppl 14 (2007) S3-S21 quiz
5. Lautenbach E., and Polk R.E. Resistant gram-negative bacilli: A neglected healthcare crisis?. Am J Health Syst Pharm. 64 Suppl 14 (2007) S22-S24
6. Mouton J.W. Breakpoints: Current practice and future perspectives. IntJ Antimicrob Agents. 19 (2002) 323-331
7. Kuti J.L., and Nicolau D.P. Making the most of surveillance studies: Summary of the OPTAMA Program. Diagn Microbiol Infect Dis. 53 (2005) 281-287
8. Gillespie E.L., Kuti J.L., and Nicolau D.P. Pharmacodynamics of antimicrobials: Treatment optimisation. Expert Opin Drug Metab Toxicol. 1 (2005) 351-361
9. Eagye K.J., Nicolau D.P., Lockhart S.R., et al. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004. Ann Clin Microbiol Antimicrob. 6 (2007) 11
10. Ambrose P.G., Bhavnani S.M., and Jones R.N. Pharmacokineticspharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: Report from the ARREST program. Antimicrob Agents Chemother. 47 (2003) 1643-1646
11. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Sixteenth informational supplement. CLSI document M100-S16 (2006), CLSI, Wayne, Pa. 1-56238-588-7
12. Tygacil [package insert] (June 2005), Wyeth Pharmaceuticals Inc, Philadelphia, Pa
13. Avelox [package insert] (October 2008), Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ
14. Tam V.H., Gamez E.A., Weston J.S., et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: Implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 46 (2008) 862-867
15. Passarell J.A., Meagher A.K., Liolios K., et al. Exposureresponse analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 52 (2008) 204-210
16. DeRyke C.A., Kuti J.L., and Nicolau D.P. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy. 27 (2007) 333-342
17. Crandon J.L., Kuti J.L., Jones R.N., and Nicolau D.P. Comparison of 2002-2006 OPTAMA programs for US hospitals: Focus on gram-negative resistance. Ann Pharmacother. 43 (2009) 220-227
18. Turnidge J.D. The pharmacodynamics of beta-lactams. Clin Infect Dis. 27 (1998) 10-22
19. Walker R., Andes D., Conklin J., et al. Pharmacodynamic activities of meropenem in an animal infection model. Abstract presented at: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando (1994), American Society for Microbiology, Washington, DC 147
20. Drusano G.L., Preston S.L., Fowler C., et al. Relationship between fluoroquinolone area under the curve: Minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 189 (2004) 1590-1597
21. Wright D.H., Brown G.H., Peterson M.L., and Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 46 (2000) 669-683
22. Meagher A.K., Ambrose P.G., Grasela T.H., and Ellis-Grosse E.J. Pharmacokinetic/ pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 52 (2005) 165-171
23. Gaynes R., Edwards J.R., and National Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 41 (2005) 848-854
24. Jones R.N., Kirby J.T., and Rhomberg P.R. Comparative activity of meropenem in US medical centers (2007): Initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis. 61 (2008) 203-213
25. DeRyke C.A., Kuti J.L., and Nicolau D.P. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis. 58 (2007) 337-344
26. Lockhart S.R., Abramson M.A., Beekmann S.E., et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol. 45 (2007) 3352-3359
27. Bradley J.S., Dudley M.N., and Drusano G.L. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 22 (2003) 982-992 quiz
28. Bradley J.S., Dudley M.N., and Drusano G.L. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 22 (2003) 993-995
29. Kuti J.L., Ong C., Lo M., et al. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents. 28 (2006) 62-68